For HER2-negative early breast cancer with BRCA1/2 germline mutations, a recent phase III OlympiA trial reported significant longer DFS (87.5% vs. 80.4%, p < 0.001) in the adjuvant Olaparib group compared to the placebo group [26]. The gene discussed is BRCA1; the disease is breast cancer.